Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1405

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: high dose FDC
DRUG: BI 10773 high dose
DRUG: high dose FDC placebo
DRUG: low dose FDC placebo
DRUG: high dose FDC placebo
DRUG: high dose FDC placebo
DRUG: low dose FDC placebo
DRUG: low dose FDC placebo
DRUG: high dose BI 10773 placebo
DRUG: low dose FDC
DRUG: high dose FDC placebo
DRUG: BI 10773 low dose
DRUG: high dose BI 10773 placebo
DRUG: high dose BI 10773 placebo
DRUG: linagliptin
DRUG: low dose FDC placebo
DRUG: linagliptin placebo
DRUG: BI 10773 low dose placebo
DRUG: linagliptin placebo
DRUG: low dose BI 10773 placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]